COV

Covalon to Participate in the 12th International Pediatric Intestinal Failure and Rehabilitation Symposium in Toronto

Retrieved on: 
Wednesday, September 28, 2022
S, Health, Sheraton Centre Toronto Hotel, Parenteral nutrition, Infection, Center, COVID-19, Twitter, Risk, FDA, CLABSI, PTN, Patient, Warner, Critical care, Company, LinkedIn, News, HAI, Learning, Rehabilitation, CVC, Forward-looking statement, TSX Venture Exchange, Survival, Phrase, CEO, Technology, Instagram, Centers for Disease Control and Prevention, Solution, Fluid mechanics, Short bowel syndrome, COV, Multimedia, Bloodstream infections, View, Hospital, Pharmaceutical industry, Cosmetics, Facebook, MISSISSAUGA

MISSISSAUGA, ON, Sept. 28, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its participation in the 12th International Pediatric Intestinal Failure and Rehabilitation Symposium in Toronto from September 30 to October 2, 2022.

Key Points: 
  • MISSISSAUGA, ON, Sept. 28, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its participation in the 12th International Pediatric Intestinal Failure and Rehabilitation Symposium in Toronto from September 30 to October 2, 2022.
  • The meeting brings together health and science professionals who are dedicated to the care of children with intestinal failure.
  • Venue: Sheraton Centre Toronto Hotel (123 Queen St W, Toronto, Ontario, Canada)
    "A single CLABSI can change the course of a patient's treatment or worse, be life threatening," said Brian Pedlar, CEO of Covalon.
  • "We need to be more proactive when it comes to protecting all patients, especially those requiring long-term I.V.

Covalon to Showcase Infection Prevention Solutions at the Association for Vascular Access Annual Scientific Meeting

Retrieved on: 
Monday, September 26, 2022
Safety, Infection, Risk, FDA, Company, News, Patient, TSX Venture Exchange, Minneapolis, Phrase, Forward-looking statement, CEO, Minneapolis Convention Center, Fluid mechanics, Caregiver, AVA, COV, Association, Hospital, Skin, Multimedia, View, Pharmaceutical industry, Cosmetics

Visit us at booth 607 to learn about advanced infection prevention solutions that reduce the burden on patients, practitioners, and caregivers.

Key Points: 
  • Visit us at booth 607 to learn about advanced infection prevention solutions that reduce the burden on patients, practitioners, and caregivers.
  • It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal.
  • IV Clear - an antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment.
  • "Effective infection prevention strategies require the best products targeted at the contributors to the risk of infection," stated Brian Pedlar, CEO of Covalon.

Covalon's Dual Antimicrobial Surgical Site Dressing Adopted by Leading US Pediatric Hospital's Congenital Heart Program

Retrieved on: 
Tuesday, September 20, 2022
Length of stay, World Journal for Pediatric and Congenital Heart Surgery, Pedlar, Congenital Heart Surgeons' Society, Length, Infection, CTS, Disenchanted Hearts Unite, MSN, Hospital, CNOR, Mitchell, Company, BSN, News, SSIS, SSI, TSX Venture Exchange, Patient, Sakati–Nyhan–Tisdale syndrome, Phrase, Forward-looking statement, AORN Journal, CEO, Technology, Infection Control & Hospital Epidemiology, Subclinical infection, Caregiver, Parent, MISSISSAUGA, RN, COV, Mortality, Multimedia, View, Dentistry, Antibiotics, Medicine, Pharmaceutical industry, Texas Children's Hospital

Advanced post-operative dressing is now used to prevent post-operative infections in patients with congenital heart conditions from birth through adulthood.

Key Points: 
  • Advanced post-operative dressing is now used to prevent post-operative infections in patients with congenital heart conditions from birth through adulthood.
  • Healing and prevention of surgical site infection are paramount for patient outcomes.
  • Using a Transparent Antimicrobial Soft Silicone Dressing to Prevent Surgical Site Infections After Congenital Heart Surgery.
  • Sochet AA, Cartron AM, Nyhan A, Spaeder MC, Song X, Brown AT, Klugman D. Surgical Site Infection After Pediatric Cardiothoracic Surgery:Impact on Hospital Cost and Length of Stay.World Journal for Pediatric and Congenital Heart Surgery.2017 Jan;8(1):7-12.

Covalon to Introduce New Infection Prevention Products at the Annual Association of Pediatric Hematology/Oncology Nurses (APHON) Conference

Retrieved on: 
Tuesday, September 13, 2022
Infection, Palm Beach County Convention Center, Risk, Nursing, FDA, Company, News, Forward-looking statement, Patient, TSX Venture Exchange, Phrase, CEO, Silver, Fluid mechanics, Pediatrics, Conference, High-dependency unit, COV, Association, Hospital, Marketing, Multimedia, Bloodstream infections, View, Chlorhexidine, Medicine, Pharmaceutical industry, MISSISSAUGA

Visit Covalon at booth 307 to learn how our infection prevention and advanced wound care products are making a difference in the lives of our youngest patients.

Key Points: 
  • Visit Covalon at booth 307 to learn how our infection prevention and advanced wound care products are making a difference in the lives of our youngest patients.
  • "Effective infection prevention strategies require the best products targeted at the contributors to the risk of infection," started Brian Pedlar, CEO of Covalon.
  • The Conference provides premier educational content, networking, and social events for nurses specializing in pediatric hematology/oncology.
  • To book an appointment with a Covalon representative, please email Ron Hebert, SVP Marketing, Covalon Technologies Ltd., at [email protected] .

Covalon Announces Expansion of its United States Pediatric Hospital Customer Base

Retrieved on: 
Thursday, September 8, 2022
COV, Phrase, CEO, Technology, Caregiver, Observation, Chlorhexidine, Physiology, View, Solution, TSX Venture Exchange, Infection, Silver, U.S. News & World Report, Hospital, Fluid mechanics, Multimedia, Company, FDA, News, Adult, Forward-looking statement, Patient, Child, Medicine, Pharmaceutical industry, MISSISSAUGA

MISSISSAUGA, ON, Sept. 8, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today announced it has now grown its pediatric hospital customer base to over 40 pediatric hospitals, which represents more than 17% of United States pediatric hospitals.

Key Points: 
  • MISSISSAUGA, ON, Sept. 8, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today announced it has now grown its pediatric hospital customer base to over 40 pediatric hospitals, which represents more than 17% of United States pediatric hospitals.
  • Becoming standard of care in a significant number of pediatric hospitals provides a strong base for Covalon to grow its presence in additional children's hospitals.
  • There are more than 250 pediatric hospitals in the United States, and they provide over 95% of transplantations, cancer programs, and tertiary care to children.
  • "It is not a mystery why 8 of the top 10 pediatric hospitals for cancer treatment in the United States are using Covalon products," said Brian Pedlar, CEO of Covalon.

Covalon Announces Issuance of Stock Options

Retrieved on: 
Wednesday, September 7, 2022
COV, Phrase, Option, Hull Trading Company, View, Board, TSX Venture Exchange, Multimedia, Indian stock exchange, Board of directors, Company, News, Forward-looking statement, Pharmaceutical industry

MISSISSAUGA, ON, Sept. 7, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is pleased to announce that the Company's Board of Directors has approved the grant of stock options (the "Options") exercisable for a total of 437,500 common shares ("Common Shares") to certain of its employees.

Key Points: 
  • MISSISSAUGA, ON, Sept. 7, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is pleased to announce that the Company's Board of Directors has approved the grant of stock options (the "Options") exercisable for a total of 437,500 common shares ("Common Shares") to certain of its employees.
  • All Options were granted pursuant to the Company's amended and restated stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange.
  • The Options shall vest 34% on the first anniversary following the date of the grant, 33% on the second anniversary following the date of the grant and 33% on the third anniversary following the date of grant.
  • The Options shall expire on the date that is five (5) years from the initial grant date.

Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2022 Financial Results

Retrieved on: 
Wednesday, August 24, 2022
COV, Baozou Big News Events, COVID-19, News, TSX Venture Exchange, Multimedia, Q&A, MD, Company, Investor, Risk, Webcast, SEDAR, Industry, Mission statement, Risk management

MISSISSAUGA, ON, Aug. 24, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV)(OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2022 financial results on Monday, August 29th, 2022, before markets open.

Key Points: 
  • MISSISSAUGA, ON, Aug. 24, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV)(OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2022 financial results on Monday, August 29th, 2022, before markets open.
  • A conference call and webcast to discuss the financial results will be held on Monday, August 29th, 2022, at 9:00am EST.
  • A recording of the call will be available by calling 1-888-390-0541 or 416-764-8677 and entering the encore replay entry code 297097# until September 12th, 2022.
  • Copies of Covalon's financial statements and MD&A can be obtained on SEDAR at www.sedar.com and under Sedar Filings on the Investors tab of Covalon's website.

Covalon Enters into Automatic Share Purchase Plan

Retrieved on: 
Thursday, June 30, 2022
COV, TSX Venture Exchange, Company, PI, Indian stock exchange, Financial adviser, Broker

MISSISSAUGA, ON, June 30, 2022 /PRNewswire/ - Covalon Technologies Ltd. (TSXV: COV) (OTCQX: CVALF) (the "Company" or "Covalon"), an advanced medical technologies company, today announced that it has entered into an automatic share purchase plan (the "Plan") with PI Financial Corp. (the "Broker") in order to facilitate repurchases of the Company's common shares (the "Shares") under its previously announced normal course issuer bid (the "NCIB").

Key Points: 
  • MISSISSAUGA, ON, June 30, 2022 /PRNewswire/ - Covalon Technologies Ltd. (TSXV: COV) (OTCQX: CVALF) (the "Company" or "Covalon"), an advanced medical technologies company, today announced that it has entered into an automatic share purchase plan (the "Plan") with PI Financial Corp. (the "Broker") in order to facilitate repurchases of the Company's common shares (the "Shares") under its previously announced normal course issuer bid (the "NCIB").
  • The ASPP has been approved by the TSX Venture Exchange (the "TSXV") and will be implemented effective as of June 29, 2022.
  • Outside of these restricted trading periods, the Company may at its discretion effect repurchases of its Common Shares through the Broker under the NCIB.
  • To learn more about Covalon, please contact:

Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2022 Financial Results

Retrieved on: 
Thursday, May 26, 2022
Risk, Company, MD, Webcast, News, Multimedia, TSX Venture Exchange, Mission statement, SEDAR, OTC, Investor, COVID-19, Industry, Baozou Big News Events, Q&A, COV, Risk management

MISSISSAUGA, ON, May 26, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTC: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2022 financial results on Monday May 30th, 2022, before markets open.

Key Points: 
  • MISSISSAUGA, ON, May 26, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTC: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2022 financial results on Monday May 30th, 2022, before markets open.
  • A conference call and webcast to discuss the financial results will be held on Monday May 30th, 2022, at 9:00am EST.
  • A recording of the call will be available by calling 1-888-390-0541 or 416-764-8677 and entering the encore replay entry code 020730# until June 13th, 2022.
  • Copies of Covalon's financial statements and MD&A can be obtained on SEDAR at www.sedar.com and under Sedar Filings on the Investors tab of Covalon's website.

Covalon Attracts Well-Known Medical Industry Sales Executive

Retrieved on: 
Thursday, May 19, 2022
Senior, Risk, Knowledge, Company, Leadership, Infection, News, Multimedia, TSX Venture Exchange, Corporate accountability for human rights violations, Innovative Solutions In Space, COVID-19, Gonzaga University, Industry, Creativity, US Commercial Real Estate Index, Technology, Endoscopy, B2B, Bachelor, Adoption, COV, Cantel, Cantel Medical Corporation, Pharmaceutical industry, Management, Risk management

MISSISSAUGA, ON, May 19, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that Mark Doolittle has joined the Company as Senior Vice President, Commercial Sales.

Key Points: 
  • MISSISSAUGA, ON, May 19, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that Mark Doolittle has joined the Company as Senior Vice President, Commercial Sales.
  • "I am delighted to welcome Mark to Covalon," said Brian Pedlar, Chief Executive Officer of Covalon.
  • Mr. Doolittle brings over 20 years of medical and B2B sales and marketing experience to Covalon.
  • Prior to joining Covalon, Mr. Doolittle spent the last 12 years at US-based Cantel Medical, the global leader in infection prevention in GI Endoscopy.